Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few

被引：1
|
作者：
Liuzzo, Giovanna [1 ,2 ]
Patrono, Carlo [1 ,3 ]
机构：
[1] Catholic Univ, Dept Cardiovasc & Pulm Sci, Sch Med, Largo F Vito 1, I-00168 Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Dept Cardiovasc Sci, Largo A Gemelli 8, I-00168 Rome, Italy
[3] Catholic Univ, Dept Pharmacol, Sch Med, Largo F Vito 1, I-00168 Rome, Italy
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 08期
关键词：
MORTALITY;
D O I：
10.1093/eurheartj/ehad823
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：570 / 571
页数：2
相关论文
共 50 条
  • [21] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [22] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Ipp, Eli
    Genter, Pauline
    Childress, Kristin
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 891
  • [23] Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes
    A. Basolo
    P. Fierabracci
    G. Salvetti
    F. Santini
    Journal of Endocrinological Investigation, 2024, 47 : 1047 - 1049
  • [24] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [25] Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial
    Colhoun, H. M.
    Kahn, S. E.
    Brown, P. M.
    Olesen, E. T. B.
    Bravo, R.
    Deanfield, J.
    Goudev, A.
    Latkovskis, G.
    Lehrke, M.
    Lincoff, A. M.
    Rathor, N.
    Wu, C. -C.
    Lingvay, I.
    DIABETOLOGIA, 2024, 67 : S80 - S81
  • [26] Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Bain, Stephen C.
    Belmar, Nicolas
    Hoff, Soren T.
    Husain, Mansoor
    Rasmussen, Soren
    Vilsboll, Tina
    Petrie, Mark C.
    DIABETES THERAPY, 2025, 16 (01) : 15 - 28
  • [27] Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial
    Lusk, Jay B.
    Glover, Lashaunta
    Soneji, Samir
    Granger, Christopher B.
    O'Brien, Emily
    Pagidipati, Neha
    AMERICAN HEART JOURNAL, 2024, 276 : 110 - 114
  • [28] Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
    Lingvay, Ildiko
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lincoff, A. Michael
    Marso, Steven P.
    Fries, Tea Monk
    Plutzky, Jorge
    Ryan, Donna H.
    OBESITY, 2023, 31 (01) : 111 - 122
  • [29] Inflammatory Markers in Cardiovascular Risk and Outcomes in SELECT
    Plutzky, Jorge
    OBESITY, 2024, 32 : 24 - 24
  • [30] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Husain, Mansoor
    Birkenfeld, Andreas L.
    Donsmark, Morten
    Dungan, Kathleen
    Eliaschewitz, Freddy G.
    Franco, Denise R.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Mosenzon, Ofri
    Pedersen, Sue D.
    Tack, Cees J.
    Thomsen, Mette
    Vilsboll, Tina
    Warren, Mark L.
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09): : 841 - 851
12345